trending Market Intelligence /marketintelligence/en/news-insights/trending/Vux1OyjbZPgdqqUZE_pfzg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novartis generics unit Sandoz enters deal to sell insulin biosimilars

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novartis generics unit Sandoz enters deal to sell insulin biosimilars

Sandoz, the generics unit of Switzerland's Novartis AG, entered a collaboration deal with China-based supplier Gan & Lee Pharmaceutical Ltd. to commercialize biosimilar versions of insulins.

The two companies will sell biosimilars — lower-cost copies of biologic medicines — of insulin medicines glargine, lispro and aspart, which are the top insulin medicines in terms of sales. The insulin therapies are used in patients with type 1 and type 2 diabetes.

Under the deal, Sandoz will be responsible for commercializing the therapies in the EU, U.S., Japan, South Korea, Canada, Australia and New Zealand. Gan & Lee will shoulder manufacturing and development of the therapies, adhering to the manufacturing requirements for Sandoz biosimilars.

Financial terms of the deal were not disclosed.

The deal allows Sandoz to enter the insulin business and expand its endocrinology portfolio in line with its strategy to expand its biosimilar business, the company said in a news release.